Leerink Partners Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Market Perform
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Monday, Marketbeat.com reports. They presently have a $2.00 price target on the stock, down from their previous price target of $33.00. Leerink Partners’ price target would […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Monday, Marketbeat.com reports. They presently have a $2.00 price target on the stock, down from their previous price target of $33.00. Leerink Partners’ price target would […]
